The Basic Principles Of Tyrosinase-IN-12
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage numerous intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important trial aims were To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis